Dear Colleagues,

Acute coronary syndromes (ACS) are the leading cause of death worldwide. The development of percutaneous treatment options dramatically improves the outcome of ACS and of ACS-related consequences. The introduction of novel pharmacological treatments have been introduced on parallel to the performance of invasive procedures. For example, novel insights into antiplatelet treatments have improved the performance of stent implantation and reduced the ACS consequences on the heart. Lipid management in the acute setting is facing a new era which is based on the need to target specific proteins able to counteract the action of lipid molecules in myocardial infarction and to prevent short-, mid- and long-term atherosclerotic alterations in coronary vessels. Advances in the knowledge of biochemical pathways mainly related to atherosclerotic plaque instability and progression forced scientific community to develop pharmaceutical compounds able to acutely block the inflammation of the vessels which is mainly responsabile for the acute and chronic progression of atherothrombosis.

The aim of this Special Issue is to collect high-quality original research papers and comprehensive reviews on recent advances in the pharmacological treatment of acute coronary syndromes in order to provide deeper insights into this ongoing topic.

Pietro Scicchitano
Guest Editor